In a major development for diabetes and weight loss management, India’s drug regulator, Central Drugs Standard Control Organisation (CDSCO), has approved Ozempic (semaglutide) for use in adults with type 2 diabetes. This means Danish drugmaker Novo Nordisk’s once-a-week injection will now be available in India on a doctor’s prescription, a significant step in a country often called the 'diabetes capital of the world.'

What is Ozempic?

Ozempic is the brand name for semaglutide, a medicine that helps regulate blood sugar in people with type 2 diabetes. First approved by the US FDA in 2017, it belongs to the class of GLP-1 receptor agonists and also supports weight management.

Why is this approval important?

India is home to one of the largest populations of people with diabetes and obesi

See Full Page